Successfully led the monitoring efforts for a pivotal Phase III oncology trial across 15 sites, reducing major protocol deviations by 25% through proactive site training and real-time data review. This critical achievement ensured robust data integrity and expedited database lock for a study with a challenging adaptive design, directly impacting submission timelines. My approach focused on early identification of potential issues, employing advanced risk-based monitoring strategies to maintain compliance with ICH-GCP guidelines while optimizing site burden.
During my tenure, I reduced Source Data Verification (SDV) discrepancies by an average of 18% across multiple Phase II/III studies by implementing targeted data review algorithms within our eCRF systems and providing customized feedback to site coordinators. I also spearheaded the rapid initiation of 10 new complex rare disease sites, ensuring 100% compliance with FDA 21 CFR Part 11 regulations and local IRB/EC requirements within an aggressive three-month timeline. Furthermore, I managed the full close-out process for a multi-national neurological study, achieving all outstanding query resolutions ahead of schedule.
I am particularly drawn to Veridian Clinical Solutions' commitment to developing innovative gene therapies, as highlighted by your recent advancements in CRISPR-based treatments for neurodegenerative diseases. My extensive experience with complex protocols and stringent regulatory environments, especially concerning novel therapies and 21 CFR Part 11 compliance for electronic systems, aligns perfectly with your pioneering work. I am confident my expertise in navigating intricate clinical landscapes and ensuring data quality will significantly contribute to your cutting-edge research endeavors.
My comprehensive understanding of clinical trial operations, coupled with a proactive monitoring approach and deep regulatory knowledge, equips me to immediately contribute to Veridian Clinical Solutions' mission. I am eager to leverage my 10 years of experience to uphold the highest standards of data integrity and participant safety within your advanced therapeutic programs. Thank you for considering my application; I look forward to discussing how my skills and accomplishments can support your team's success.
Best regards,
Grace Okonkwo